/

Società

Ka

Non verificato

Kardigan

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaIndustriaSalute

6 comunicati stampa

Guarda tutti i comunicati

07/11/2025

Farmaceutica

Salute

Medicina - Varie

Cardiologia

Industria

Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025

Fonte

Emittente

1.00

0

14/10/2025

Biotecnologia

Farmaceutica

Salute

Cardiologia

Industria

Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio of Personalized Cardiovascular Medicines

Fonte

Emittente

1.00

0

29/09/2025

Eventi

Industria

Salute

Medicina - Varie

Farmaceutica

Cardiologia

Biotecnologia

Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025

Fonte

Emittente

1.00

0

25/09/2025

Industria

Salute

Medicina - Varie

Farmaceutica

Cardiologia

Biotecnologia

Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis

Fonte

Emittente

1.00

0

27/03/2025

Multimedialità

Mercato azionario

Salute

Tecnica

Software

Farmaceutica

Cardiologia

Biotecnologia

Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform

Fonte

Emittente

1.00

0

10/01/2025

Mercato del lavoro

Scienza

Cardiologia

Biotecnologia

Farmaceutica

Salute

Associazioni/Professionisti

Kardigan Launches with Industry-Leading Team to Modernize Cardiovascular Drug Development with Late-Stage Portfolio of Personalized Medicines

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0